# A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia

> **NCT05995054** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 110 (estimated)

## Conditions studied

- Immune Thrombocytopenia
- Treatment

## Interventions

- **DRUG:** Obinutuzumab Injection [Gazyva]

## Key facts

- **NCT ID:** NCT05995054
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-28
- **Primary completion:** 2025-08
- **Final completion:** 2026-08
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05995054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05995054, "A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05995054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*